Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated

Mayo Clinic Proceedings

Volumn 83, Issue 12, 2008, Pages 1316-1325

  Jacobson, Terry A ^a   Wertz, Debra A ^b   Hoy, Tracey ^b   Kuznik, Andreas ^c   Grochulski, Daniel ^b   Cziraky, Mark ^b  

^a EMORY UNIVERSITY   (United States)

^b HEALTHCORE INC   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION;

EID: 57349200562     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.12.1316     Document Type: Article

References (50)

1. Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 Jan 29;117(4):e25-e146. Epub 2007 Dec 17.
2. American Heart Association. Cardiovascular Disease Statistics Web site. http://www.americanheart.org/presenter.jhtml?identifier=4478. Accessed October 21, 2008.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
4. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines [published correction appears in Circulation. 2004;110(6):763]. Circulation. 2004;110(2):227-239.
5. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97(10):946-952.
6. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J. 2000;139(4):577-583.
7. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
8. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001-1009.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
10. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998;82(1):128]. Am J Cardiol. 1998;81(5):582-587.
11. Olsson AG, Istad H, Luurila O, et al; Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144(6):1044-1051.
12. Downs JR, Clearfield M, Weis S, et al; AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622.
13. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
14. IMS Annual Report on Prescription Drug Trends (Feb 20, 2006). IMS Health Web site. http://www.imshealth.com. Accessed June 18, 2008.
15. Pedersen TR, Faergeman O, Kastelein JJ, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [published correction appears in JAMA. 2005;294(24):3092]. JAMA. 2005;294(19):2437-2445.
16. Nawrocki JW, Weiss SR, Davidson MH, et al; West of Scotland Coronary Prevention Study Group. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15(5):678-682.
17. Shepherd J, Cobbe SM, Ford I, et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-1307.
18. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220-228.
19. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006;354(7):778]. N Engl J Med. 2004 Apr 8;350(15):1495-1504. Epub 2004 Mar 8.
20. Koren MJ. Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Am J Med. 2005;118(12A):16S-21S.
21. LaRosa JC, Grundy S, Waters DD. Intensive lipid lowering with atorvastatin provides early and sustained benefit in patients with stable coronary disease: a secondary analysis of the Treating to New Targets (TNT) study [abstract 3728]. Circulation 2006;114(suppl 2):796.
22. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 7;352(14):1425-1435. Epub 2005 Mar 8.
23. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004 Aug 10;110(6):674-678. Epub 2004 Jul 26.
24. Pitt B, Waters D, Brown WV, et al; Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341(2):70-76.
25. Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
26. Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92(2):152-160.
27. Gentile S, Turco S, Guarino G, et al. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes Obes Metab. 2000;2(6):355-362.
28. Sharpe N. Clinical trials and the real world: selection bias and generalizability of trial results. Cardiovasc Drugs Ther. 2002;16(1):75-77.
29. Lloyd-Williams F, Mair F, Shiels C, et al. Why are patients in clinical trials of heart failure not like those we see in everyday practice? J Clin Epidemiol. 2003;56(12):1157-1162.
30. Badano LP, Di Lenarda A, Bellotti P, Albanese MC, Sinagra G, Fioretti PM. Patients with chronic heart failure encountered in daily clinical practice are different from the "typical" patient enrolled in therapeutic trials. Ital Heart J. 2003;4(2):84-91.
31. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 2006 Apr;26(4):469-478.
32. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002;113(8):625-629.
33. Phillips B, Roberts C, Rudolph AE, Morant S, Aziz F, O'Regan C. Switching statins: the impact on patient outcomes. Br J Cardiol. 2007;14:280-285.
34. Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther. 2005;22(2):163-171.
35. Lachaine J, Rinfret S, Merikle EP, Tarride JE. Persistence and adherence to cholesterol lowering agents: evidence from Régie de L'Assurance Maladie du Québec data. Am Heart J. 2006;152(1):164-169.
36. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005 Oct;61(9):667-674. Epub 2005 Oct 19.
37. Foody JM, Joyce AT, Rudolph AE, Lui LZ, Benner JS. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther. 2008;30(1):195-205.
38. Dieleman JP, van Wyk JT, van Wijk MA, et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin. 2005;21(9):1461-1468.
39. Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome [letter]. Lancet. 2007;369(9555):27.
40. Usher-Smith JA, Ramsbottom T, Parmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract. 2007;61(1):15-23.
41. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005 Nov 15;162(10):1016-1023. Epub 2005 Sep 28.
42. Choudhry NK, Levin R, Winkelmayer WC. Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart. 2007 Aug;93(8):945-951. Epub 2007 Mar 7.
43. McCormack T, Minhas R. Switching statins: do it, but do it properly [editorial]. Br J Cardiol. 2007;14(5):251-252.
44. American Heart Association Web site. Cardiovascular Disease Cost. http://www.americanheart.org/presenter.jhtml?identifier=4475. Accessed October 22, 2008.
45. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
46. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
47. Nuttall M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol. 2006;59(3):265-273.
48. de Lemos JA, Blazing MA, Wiviott SD, et al; A to Z Investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 Sep 15;292(11):1307-1316. Epub 2004 Aug 30.
49. Brown WV, Bays HE, Hassman DR, et al; Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J. 2002;144(6):1036-1043.
50. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published corrections appear in Lancet. 2005;366(9494):1358 and 2008;371(9630):2084]. Lancet. 2005 Oct 8;366(9493):1267-1278. Epub 2005 Sep 27.